RESEARCH TRIANGLE PARK, N.C., June 20 /PRNewswire/ -- Peter F. Young, President and CEO of AlphaVax, Inc., has been elected Chairman of the Board of Directors of the North Carolina Biosciences Organization. "NCBIO is a strong voice for the life science industry in North Carolina and a significant factor in maintaining North Carolina's position as one of the premier biotechnology regions in the country," Young stated in accepting his new role with NCBIO. "I am looking forward to working with our member companies to help build an even stronger bioscience industry in North Carolina."
Young replaces John Funkhouser, who served as Chairman of the group from 2003 to 2005. Young has 25 years experience in the global life science industry. Prior to AlphaVax, Young held positions at Abbott International and Glaxo Wellcome.
"The life science industry has helped transform North Carolina since the original visionary establishment of Research Triangle Park a generation ago. NCBIO has been a strong advocate for the impact this critical industry can exert on North Carolina's economic future, and plays a key role with the state's decision-makers. We plan to expand that role in the coming year and strengthen the life science network across North Carolina," Young said.
The North Carolina Biosciences Organization (NCBIO) is the trade association of the life sciences industry in North Carolina. The Organization presently consists of more than 100 companies and institutions working in such diverse areas as human therapeutics, medical devices, diagnostics, agricultural biotechnology, and environmental remediation.
In addition to Young's election, the NCBIO Board named Sam Taylor as President of the Organization. Taylor previously served NCBIO's Executive Vice President. "Sam has been instrumental in the development of the organization and one of the most effective voices for the industry at the General Assembly," said Young. Taylor recently received the Council for Entrepreneurial Development's President's Service Award.
"North Carolina's government officials have long recognized the bioscience industry as both a source of new jobs and of improved quality of life," said Taylor. "NCBIO's job is to help our leaders understand how to best support the continued growth of this industry."
The Board also elected three Vice Chairmen, J. Donald deBethizy (President, Targacept, Inc.), Ken Lee (General Partner, Hatteras Biocapital), and Eric Ward (CEO, CropSolution, Inc.). Tim Gupton (Partner, Hughes Pittman & Gupton) was re-elected Treasurer of the Organization, and Brenda Summers was elected Secretary.
NCBIO Board Members are
* Dr. Leslie Alexandre, President and Chief Executive Officer, North
Carolina Biotechnology Center
* Judith Beach, Vice President and Senior Associate General Counsel,
* Dennis Burns, Partner, TCG Group/Curasan
* Dr. Charles Goldstein, Vice President Research & Director,
* Matthew Jennings, Senior Vice President and General Manager,
* Bruce Kaylos, Managing Director, Wyeth
* Joel Marcus, CEO, Alexandria Real Estate Equities, Inc.
* Matthew Megaro, President and CEO, Quill Medical
* David Miller, Director, Public Policy, GlaxoSmithKline
* Mark Paige, Vice President, Technical Operations, Novozymes
* Dr. Brandon Price, Vice President Biotechnology Services,
* Russ Read, Executive Director, National Center for the Biotechnology
* Thomas Staab, Chief Financial Officer Inspire Pharmaceuticals, Inc.
* Mark Weedon, President, BWA Consulting
* Kevin Wiley, Senior Counselor, CapStrat
"We have a great team of officers and Board members for the coming year who will provide solid direction for NCBIO and help us maximize the contribution we can make to the progress of life science companies in North Carolina," Young said.
For more information about NCBIO visit www.ncbioscience.org .
North Carolina Biosciences Organization